FDA Approves Neurotech Company for Testing Brain Chip in Humans
Activist Post reports that brain-computer interface, or BCI, represents the latest frontier of artificial intelligence and biology. While this technology is still early in development, a growing number of companies are already looking at its commercial applications.
On July 28, one of those companies, New York startup Synchron, received FDA approval to test its brain device in human patients. Stentrode, Synchron’s implantable device is small enough to be implanted via a blood vessel at the base of the neck. The device is then maneuvered toward a vessel in the brain.
Stentrode works by communicating through a tiny wire with a second implant in the chest. A transmitter then sends signals to an external computer near the patient.
“We have worked together to pave a pathway forward, towards the first commercial approval for a permanently implanted BCI for the treatment of paralysis”, Thomas Oxley, Synchron CEO, said via Activist Post.
The company plans to enroll six patients in its U.S. trial later this year. According to Oxley, the U.S. study will take a closer look at safety issues, including physical risks and cybersecurity. Activist Post reports an FDA-approved product could be on the market in as soon as 3 to 5 years.
Follow us on social media for the latest updates in B2B!
Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale
